LitAlert ~~

    • Discovery of 4-Hydroxyquinazoline Derivatives as Small Molecular BET/PARP1 Inhibitors That Induce Defective Homologous Recombination and Lead to Synthetic Lethality for Triple-Negative Breast Cancer Therapy.
    • Zhang J, Yang C, Tang P, Chen J, Zhang D, Li Y, Yang G, Liu Y, Zhang Y, Wang Y, Liu J, Ouyang L.
    • J Med Chem. 2022 Apr 20. doi: 10.1021/acs.jmedchem.2c00135. Epub ahead of print.
    • Development of a clinical polygenic risk score assay and reporting workflow.
    • Hao L, Kraft P, Berriz GF, Hynes ED, Koch C, Korategere V Kumar P, Parpattedar SS, Steeves M, Yu W, Antwi AA, Brunette CA, Danowski M, Gala MK, Green RC, Jones NE, Lewis ACF, Lubitz SA, Natarajan P, Vassy JL, Lebo MS.
    • Nat Med. 2022 Apr 18. doi: 10.1038/s41591-022-01767-6. Epub ahead of print.

    Research news: Clinical Polygenic Risk Assay, Reporting Pipeline Shows Promise for Multiple Conditions. (GenomeWeb)

    Research news: New PRS for Six Common Diseases to Aid Patient, Physician Healthcare Decisions. (Inside Precision Medicine)